Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

The integration of cancer biomarkers into oncology has revolutionized cancer treatment,
yielding remarkable advancements in cancer therapeutics and the prognosis of cancer …

Programmed cell death protein 1 (PD-1) inhibitors have modest efficacy as a monotherapy
in hepatocellular carcinoma (HCC). A personalized therapeutic cancer vaccine (PTCV) may …

Circulating tumour DNA (ctDNA) can be used to detect and profile residual tumour cells
persisting after curative intent therapy. The study of large patient cohorts incorporating …

Immune checkpoint blockade (ICB) has revolutionized modern cancer therapy, arousing
great interest in the neuro-oncology community. While several reports show that subsets of …

Background Neoadjuvant chemotherapy and radiation followed by surgical resection of the
rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is …

Tumor microenvironment (TME) is a specialized ecosystem of host components, designed
by tumor cells for successful development and metastasis of tumor. With the advent of 3D …

Cancer immunotherapies, including adoptive T cell transfer, can be ineffective because
tumors evolve to display antigen-loss-variant clones. Therapies that activate multiple …

DNA mismatch repair deficiency (MMRd) is associated with a high tumor mutational burden
(TMB) and sensitivity to immune checkpoint blockade (ICB) therapy. Nevertheless, most …

Abstract Human papillomavirus (HPV)-positive (HPV+) oropharyngeal squamous cell
carcinoma (OPSCC) has one of the most rapidly increasing incidences of any cancer in high …